IGC Pharma Balance Sheet Health
Financial Health criteria checks 6/6
IGC Pharma has a total shareholder equity of $9.1M and total debt of $141.0K, which brings its debt-to-equity ratio to 1.6%. Its total assets and total liabilities are $11.3M and $2.2M respectively.
Key information
1.6%
Debt to equity ratio
US$141.00k
Debt
Interest coverage ratio | n/a |
Cash | US$1.38m |
Equity | US$9.05m |
Total liabilities | US$2.21m |
Total assets | US$11.26m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: IGC's short term assets ($3.6M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: IGC's short term assets ($3.6M) exceed its long term liabilities ($270.0K).
Debt to Equity History and Analysis
Debt Level: IGC has more cash than its total debt.
Reducing Debt: IGC's debt to equity ratio has reduced from 4.3% to 1.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IGC has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IGC is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.